Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data.
Robert Løvsletten SmithEspen MoldenJean-Paul BernardPublished in: British journal of clinical pharmacology (2023)
CYP2D6 genotype has a great impact on atomoxetine exposure, where our real-world data suggest atomoxetine dose requirements to be around half and 1/10 in CYP2D6 IM and PM vs. NM patients, respectively. When adding CYP2C19 genotype as a factor of relevance for personalized atomoxetine dosing, CYP2C19*2 carriers should further reduce the dose by a third. These findings suggest that pre-emptive CYP2D6/CYP2C19 genotyping should be performed to individualize atomoxetine dosing and prevent adverse effects.
Keyphrases
- attention deficit hyperactivity disorder
- autism spectrum disorder
- end stage renal disease
- electronic health record
- ejection fraction
- newly diagnosed
- big data
- chronic kidney disease
- working memory
- peritoneal dialysis
- photodynamic therapy
- prognostic factors
- heavy metals
- artificial intelligence
- polycyclic aromatic hydrocarbons